Physician profile
David P Reyes
NPI 1457448557
$10,994.22
in general payments reported to CMS, 2019-2025
32 companies · $1,700 in 2025
The $1,700 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,227 · 2020: $436 · 2021: $346 · 2022: $3,206 · 2023: $1,552 · 2024: $2,526 · 2025: $1,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,778.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,894.85 | 2022-2025 | |
| Novo Nordisk INC | $1,546.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,084.42 | 2019-2025 | |
| Glaxosmithkline, LLC. | $915.70 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $692.11 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $424.87 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $412.60 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $361.87 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $333.28 | 2019-2024 | Xarelto, Spravato |
| Amgen INC. | $323.45 | 2019-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $295.86 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $225.98 | 2019-2023 | |
| Exact Sciences Corporation | $219.08 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $213.94 | 2019-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $201.11 | 2019-2025 | Veozah |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $150.01 | 2024-2025 | Zenpep |
| Otsuka America Pharmaceutical, INC. | $86.96 | 2023-2024 | Rexulti |
| Sumitomo Pharma America, INC. | $81.37 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $80.85 | 2019-2025 | Capvaxive |
| Allergan, INC. | $72.98 | 2019-2020 | |
| Atricure, INC. | $49.84 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Dynavax Technologies Corporation | $48.56 | 2023-2025 | Heplisav-B |
| Eisai INC. | $46.24 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.07 | 2019-2020 | |
| Inspire Medical Systems, INC. | $44.13 | 2024 | Inspire |
| Medtronic Vascular, INC. | $40.58 | 2019 | |
| Corcept Therapeutics | $24.42 | 2024 | Korlym |
| Daiichi Sankyo INC. | $19.00 | 2023 | Injectafer |
| Philips North America LLC | $18.22 | 2024 | (Ck7) Extended Holter |
| Biohaven Pharmaceutical Holding Company LTD. | $15.31 | 2022 | |
| Mannkind Corporation | $13.17 | 2023 | Afrezza |
| Cequr Corporation | $11.34 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.